IL4R Recombinant Antibody: Enhance Your Research with Quality Solutions

Experience groundbreaking research with the IL4R recombinant antibody from Alpha Lifetech Incorporation. This high-quality antibody is designed specifically to target the Interleukin 4 receptor (IL4R), a vital component in immune response modulation and pathogenesis of various diseases, including asthma and allergies. Utilizing advanced recombinant technology, this antibody boasts exceptional specificity and affinity, ensuring reliable performance in various applications such as Western blot, ELISA, and immunohistochemistry, Alpha Lifetech is committed to providing researchers with tools that enhance the understanding of immune mechanisms and facilitate innovative therapeutic developments. The IL4R recombinant antibody stands as a testament to our dedication to quality and precision. With rigorous validation processes and high standards of production, this antibody supports your research endeavors in elucidating the role of IL4R in disease contexts. Elevate your studies with the IL4R recombinant antibody and unlock new insights in immunology research

Hot Selling Product

ADT1332-J695 Biosimilar-Recombinant Human Monoclonal Antibody

ALP64510-Recombinant Cynomolgus Monkey SIRP alpha/CD172a Protein, His Tag

ALP64562-Recombinant Rhesus Macaque CD160 Protein, Fc Tag

ALP64512-Recombinant Human CD96 Protein, Fc Tag

ALP64518-Recombinant Human Tie-2 Protein, Fc Tag

Trending IL4R recombinant antibody Exceeds Industry Benchmarks Where Innovation Meets 2025

In the ever-evolving landscape of biopharmaceutical research, the demand for innovative recombinant antibodies has surged. Alpha Lifetech Inc., a pioneer founded by seasoned scientists specializing in membrane Protein production and monoclonal development, is at the forefront of this transformation. Our latest innovation, the IL4R recombinant antibody, not only meets industry expectations but exceeds them, setting a new benchmark for quality and efficacy as we anticipate 2025's challenges. With a robust portfolio of nearly 10,000 high-quality reagents, cytokines, and drug target antibodies, Alpha Lifetech Inc. has become synonymous with excellence in the biotechnological sector. Our IL4R recombinant antibody stands as a testament to our commitment to innovation. Designed through rigorous research and a deep understanding of the molecular intricacies of membrane proteins, this antibody provides unparalleled accuracy and performance, making it an invaluable asset for researchers and global procurers alike. Join us in advancing the frontiers of scientific exploration with the IL4R recombinant antibody. As we continue to innovate and improve our offerings, we invite buyers and researchers around the world to partner with Alpha Lifetech Inc. for high-quality tools that drive discovery and therapeutic development. Together, let’s redefine what’s possible in biopharmaceutical research.

Trending IL4R Recombinant Antibody Exceeds Industry Benchmarks Where Innovation Meets 2025

Metric	IL4R Recombinant Antibody	Industry Benchmark	Percentage Exceedance
Binding Affinity (Kd)	0.5 nM	1.2 nM	58.33%
Specificity	97%	85%	14.12%
Purity	99%	95%	4.21%
Production Yield	90 mg/L	70 mg/L	28.57%
Stability (months)	24	18	33.33%

Antibody Efficacy Comparison Over 12 Months

This chart illustrates the comparative efficacy of two subject groups, A and B, alongside the established industry benchmarks over a 12-month period. The data reflects a significant trend in efficacy performance, showcasing Subject A's superior results compared to Subject B throughout the year. Notably, Subject A maintains a consistent improvement, surpassing the industry benchmark significantly. The line for Subject B indicates a more stable but lesser efficacy progression, remaining above the benchmark only marginally. This data visualization highlights the importance of innovation in antibody development and its impact on efficacy, setting potential new standards in the industry as we approach 2025. Continuous monitoring and analysis of these trends will be crucial for future advancements in therapeutic applications.